Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Vertical Diplopia
Semin Neurol 20:21-30, Acierno,M.D., 2000
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Immunologic Aspects of Neurological & Neuromuscular Diseases
JAMA 258:2970-2973, Zweiman,B.&Arnason,B.G.W., 1987
Acute Bilateral Ophthalmoplegia:60 Cases
Neurol 36:279-281, Keane,J.R., 1986
Abnormalities of Eyelid Closure
In Walsh & Hoyt's Clinical Neuro-ophthalmology, Williams & Wilkins, Baltimore, 2:967, Miller,M.R., 1985
Clinical Pathological Conference
Giant-cell Arteritis of Temporal Artery (temporal arteritis) , Case Record 35-1977, NEJM 297:4927., , 1977
Neurosyphilis
JAMA 219:726, Hooshmand,H.,et al, 1972
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
The Face of Myasthenia Gravis
Neurol 95:89-90, Ruiter, A.M.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Differential Diagnosis of Finger Drop
Neurologist 19:128-131, Varatharaj, A.,et al, 2015
Juvenile Myasthenia Gravis: Recommendations for Diagnostic Approaches and Treatment
Neuropediatrics 45:75-83, Marina, A.D.,et al, 2014
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Respiratory Management in Acute Neurologic Illness
Neurol 50:11-20, Wijdicks,E.F.M.&Borel,C.O., 1998
Binocular Vertical Diplopia
Mayo Clin Proc 73:55-66, Brazis,P.W.&Lee,A.G., 1998
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Pure Motor Hand Weakness
Semin Neurol 16:75-81, Lewis,R.A., 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Congenital Myasthenic Syndromes
In:Neurologic Clinics, 12:401-4371994., Engel,A.G., 1994
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993
Continuous Muscle Fiber Activity, Peripheral Neuropathy, and Thymoma
Ann Neurol 29:215-218, Garcia-Merino,A.,et al, 1991
Myasthenia Gravis and Recurrent Guillain-Barre Syndrome
Neurol 41:1848, Carlander,B.,et al, 1991
Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990
Sharing of Antigenic Determinants Between the Nicotinic Ach Receptor & Proteins in Ecoli, Prot Vulgaris & Pneumoniae
NEJM 312:221-225, Stefansson,K.,et al, 1985
Myasthenia Gravis & Myasthenic Syndromes
Ann Neurol 16:519-534, Engel,A.G., 1984
Myasthenia Gravis:Mechanisms & Management
Hospital Practice, (March) , 101-1093., Lisak,R.P., 1983
Myasthenia Gravis
JAMA 250:2516-2521, Seybold,M.D., 1983
Pathogenesis & Treatment of Myasthenia Gravis
BMJ 283:1008-1012, Scadding,G.K.,et al, 1981